Mederi draws $18.5M Series B to expand reach of GI treatment devices

Mederi Therapeutics grabbed $18.5 million in new financing to back an expanded commercial push for treatment devices that address gastroesophageal reflux disease and bowel incontinence. Acadia Woods Partners, Respiratory Diagnostics (a Bio-Rad Laboratory subsidiary) and a number of high-net-worth equity investors participated in the Series B financing, which involved preferred stock and venture debt. Greenwich, CT-based Mederi makes and sells medical devices that use radiofrequency energy to treat digestive system-related diseases. Item

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.